All articles tagged with #glp 1 agonists
Research from Virginia Tech suggests that weight loss drugs, specifically GLP-1 agonists, delay alcohol absorption, reducing the immediate effects and potentially helping people cut back on drinking, which could be beneficial for alcohol use disorder treatment.
Research warns of dangers associated with starting and stopping weight loss shots like Semaglutide, including serious side effects, potential for weight regain, and muscle loss. Medical professionals emphasize the importance of understanding risks, addressing underlying health issues, and adopting sustainable lifestyle changes to maintain weight loss long-term. A special offer for a comprehensive health assessment is available at Health Utah.
Research warns of dangers from starting and stopping weight loss shots like Semaglutide, including serious side effects and weight regain. Medical professionals highlight risks such as severe pain, organ issues, and potential death, emphasizing the importance of informed decision-making and comprehensive health strategies for sustainable weight management.
Research warns of dangers from starting and stopping weight loss shots like Semaglutide, including serious side effects and weight regain. Medical professionals highlight risks such as severe pain, organ issues, and potential death, emphasizing the importance of informed decisions and comprehensive health strategies for sustainable weight management. Dr. Roberts advocates for addressing underlying health issues and adopting personalized, holistic approaches to maintain weight loss without relying solely on medication.
A Japanese study suggests that emotional eating may reduce the effectiveness of weight loss drugs like Ozempic, as emotional eaters tend to revert to unhealthy habits over time, potentially due to underlying psychological issues. External eaters, however, continue to improve, indicating that behavioral and psychological support might enhance treatment outcomes. Further research is needed to confirm these findings and improve personalized treatment strategies.
A study suggests that GLP-1 drugs like Ozempic are more effective for individuals whose overeating is triggered by external cues rather than emotional reasons, highlighting the importance of behavioral assessments in treatment planning.
A large study shows that weight loss drugs like semaglutide and tirzepatide can significantly reduce the risk of hospitalization and early death in heart failure patients with obesity and type 2 diabetes, potentially offering a new treatment avenue for these patients.
The term 'Ozempic vulva' refers to sagging skin and other changes in the vulvar area reported by women using GLP-1 agonists like Ozempic for weight loss, likely due to rapid fat loss and muscle weakening. While some opt for non-invasive treatments like moisturizers or pelvic exercises, others consider procedures such as labia puffing or labiaplasty. More scientific research is needed to understand these effects fully.
Recent studies suggest that GLP-1 agonist drugs like Ozempic and Wegovy, used for weight loss and diabetes management, may carry a small risk of serious eye conditions such as NAION and diabetic retinopathy, but the overall risk appears modest and requires further research. Patients with risk factors should consult their doctors and undergo regular eye exams to monitor eye health while on these medications.
A recent study suggests that GLP-1 agonists may offer better protection against dementia in people with type 2 diabetes compared to metformin, with findings indicating a significantly lower risk of developing dementia and Alzheimer’s disease among GLP-1 users. The research highlights the potential neuroprotective benefits of GLP-1 medications, which could influence future treatment strategies for diabetes and cognitive decline.
A pilot study suggests that GLP-1 agonists like liraglutide, originally used for diabetes and weight loss, may significantly reduce the frequency of chronic migraines, potentially through mechanisms independent of weight loss, such as lowering intracranial pressure. Further research is needed to confirm these findings.
A clinical trial suggests that Ozempic-like drugs, specifically semaglutide, may be effective in treating type 1 diabetes by improving blood sugar control and promoting weight loss, potentially offering a new treatment option alongside insulin. The study involved 72 obese type 1 diabetics, with results showing better blood sugar management and weight loss in those treated with semaglutide, though more research is needed for regulatory approval.
A study published in JAMA Psychiatry suggests that GLP-1 agonists, such as Ozempic and Wegovy, may help treat alcohol use disorder. The research, which analyzed data from over 227,000 individuals in Sweden, found that users of these drugs had a significantly lower risk of hospitalization due to alcohol-related issues compared to non-users. While the findings are promising, researchers emphasize the need for clinical trials to confirm these associations and assess the safety of using these medications for addiction treatment.
Recent research from the University of Alberta suggests that semaglutide, the active ingredient in popular weight loss drugs like Ozempic, may reduce heart muscle size in mice, raising concerns about potential long-term effects on cardiac health. While the study found no changes in heart function, the reduction in cardiac size occurred independently of weight loss. The implications for humans, particularly those with cardiovascular issues, remain uncertain, prompting calls for further investigation into the effects of GLP-1 agonists on heart and muscle health.
Susan McGowan, a 58-year-old NHS bed manager, has become the first confirmed fatality linked to the weight loss drug Mounjaro, also known as tirzepatide, after suffering severe complications following two doses. Her death certificate cites multiple organ failure, septic shock, and pancreatitis, with Mounjaro usage as a contributing factor. Despite being approved by the NHS, McGowan purchased the drug privately. The incident has raised concerns about the safety of GLP-1 agonists, though the MHRA maintains that the benefits outweigh the risks when used correctly.